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The D’Amico risk group classification was originally developed to estimate the risk of biochemical
recurrence following treatment for localized prostate cancer. We validated the ability of the risk group to
predict biochemical recurrence after radical prostatectomy for patients with high-risk prostate cancer. We
retrospectively reviewed the medical records of 208 patients who underwent radical prostatectomy, excluding
patients with neoadjuvant hormonal therapy, with adjuvant hormonal therapy or radiotherapy, and patients
without significant clinical data at our institution between 1997 and 2005. Using the D’Amico risk criteria,
58 (28%), 100 (48%), 50 (24%) were stratified as low-, intermediate- and high-risk groups, respectively.
The Kaplan-Meier analysis of biochemical progression-free survival showed that the high-risk group in the D’
Amico risk criteria consisted of patients with various prognosis. Therefore, in this group, patients with two
or more of three factors including clinical stage T2b or higher, preoperative PSA 10 ng/ml or greater, and
biopsy Gleason score 7-10 were reclassified into the very-high-risk group, and those with only one of three
factors were reclassified into the semi-high risk group. Patients in the very-high risk group had recurrence at
a significantly higher rate than those in the semi-high risk group (p＝0. 021). In conclusion, further
classification of the D’Amico high risk group into two subgroups has a potential to identify a patient group
with very high risk of PSA recurrence after prostatectomy.
(Hinyokika Kiyo 58 : 319-324, 2012)
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わち，低リスク群は cT1c または cT2a かつ術前 PSA
＜10 ng/ml かつ前立腺生検グリソンスコア (GS)≦6，
中リスク群は cT2b または 10＜術前 PSA≦20 ng/ml
または生検 GS＝7，高リスク群は cT2c または術前
PSA＞20 ng/ml または生検 GS≧8 と定義した．高リ
















test，Mann-whitney U test，Kruskal-Wallis test を用い
た．生存率は Kaplan-Meier 法を用いて Log rank 法に





No pts 208 58 100 50
Median age at surgery (yrs) (range) 68 (49-76) 66 (50-76) 68 (49-76) 68 (55-75) 0.47*
Median preop PSA (ng/ml) 9.0 (2.2-120) 5.5 (2.2-9.9) 9.8 (2.8-18.7) 15.0 (3.4-120) ＜0.0001*
No clinical stage (％) 0.01*
T1c 138 (66) 46 (79) 61 (61) 31 (62)
T2a 36 (17) 12 (21) 16 (16) 8 (16)
T2b 26 (13) 0 23 (23) 3 (6)
T2c 8 (4) 0 0 8 (16)
No biopsy Gleason score ＜0.0001*
6 or less 88 (42) 58 (100) 18 (18) 12 (24)
7 91 (44) 0 82 (82) 9 (18)
8-10 29 (14) 0 0 29 (58)
No pathological tumor stage (％) ＜0.0001*
T2N0 115 (55) 46 (79) 51 (51) 18 (36)
T3aN0 76 (37) 11 (19) 41 (41) 24 (48)
T3bN0 10 (5) 1 (2) 5 (5) 4 (8)
T4N0 1 (1) 0 0 1 (2)
TxN＋ 6 (2) 0 3 (3) 3 (6)
No pathological Gleason score (％) ＜0.0001*
6 or less 55 (26) 30 (52) 16 (16) 9 (18)
7 122 (59) 26 (45) 73 (73) 23 (46)
8-10 31 (15) 2 (3) 11 (11) 18 (36)
No pos surgical margin (％) 58 (28) 9 (16) 28 (28) 21 (42) 0.009**
* Kruskal Wallis test, ** χ square test.
て有意差を検定した．なお，p＜0.05 を有意差ありと
判定しているが， 3群間で有意差が出た場合の多重比















して高かった (Fig. 1 ; p＜0.001）．
続いて高リスク群についてさらに検討した．高リス
ク群該当因子数で分類したところ， 1因子のみ該当群
が42例， 2因子該当群が 8例， 3因子該当群は 0例で
あった． 1因子のみ該当群と 2因子該当群を比較した
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Fig. 1. Biochemical recurrence-free survival after RRP according to the D’Amico risk group
stratification. Pairwise low vs intermediate p＝0.113, intermediate vs high p＜0.001
and low vs high p＜0.001.
泌58,07,02-2
Fig. 2. Biochemical recurrence-free survival after RRP according to the number of high-risk
factors in D’Amico high-risk patients. One risk factor vs Two risk factors p＝0.006.
ところ， 5年非再発生存率は 1因子のみ該当群が有意





cT2b 以上，○2 術前 PSA10 以上，○3 生検 GS7 以上の
3 因子中 1 因子のみ該当する症例を準高リスク群
(semi-high リスク群）（27例）， 2因子以上該当する症
例を超高リスク群 (very-high リスク群）（23例）と定
義した．両群の臨床病理学的背景を Table 2 に示した
が，術前 PSA 値以外で統計学的に有意差のある項目
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Table 2. The characterics of the high risk patients
Feature Semi-high Very-high p value




67 (55-74) 69 (58-75) 0.17*
Median preop
PSA (ng/ml) 8.8 (3.4
-120) 17.5 (10.5-48.4) 0.01*
No pathological
tumor stage (％) 0.37*
T2N0 10 (37) 8 (35)
T3aN0 15 (55) 9 (39)
T3bN0 1 (4) 3 (13)
T4N0 0 1 (4)
TxN＋ 1 (4) 2 (9)
No pathological
Gleason score 0.26*
6 or less 7 (26) 2 (9)
7 12 (44) 11 (48)
8-10 8 (30) 10 (43)
No pos surgical
margin (％) 9 (33) 12 (52) 0.18**
* Mann-Whitney U test, ** chi square test.
はなかった．両群での 5年非再発生存率は，準高リス
ク群63％，超高リスク群26％であり，有意に超高リス
ク群の再発率が高かった (Fig. 3 ; p＝0.021）．癌死 3
例の内訳は， 1例が中リスク群， 2例が超高リスク群
泌58,07,02-3
Fig. 3. Biochemical recurrence-free survival after RRP according to the modified risk group
stratification. In D’Amico high-risk patients, those with two or more of three factors
including clinical stage T2b or higher, preoperative PSA 10 ng/ml or greater, and
biopsy Gleason score 7-10 were reclassified as very-high risk group, and those with











該当する PSA 19 ng/ml，GS4＋3，cT2b の患者が，高


























を同定し，リンパ節転移陽性27例中26例が PSA 7 以
上かつ PSA 10.5 ng/ml 以上であったこと，そして




















表された UCSF-CAPRA スコアは，術前 PSA，生検
GS，術前 T ステージ，生検陽性コア率，年齢の 5項
目を点数化し，合計点で層別化する手法である4)．日
本人に対する妥当性も報告されており，今後普及する





が，本検討での高リスク群50例の中で 4＋3 症例が 2
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